Literature DB >> 23536666

CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells.

Nora Manzke1, Ilseyar Akhmetzyanova, Kim J Hasenkrug, Mirko Trilling, Gennadiy Zelinskyy, Ulf Dittmer.   

Abstract

Conventional CD4(+) T cells play an important role in viral immunity. In most virus infections, they provide essential help for antiviral B and T cell responses. In chronic infections, including HIV infection, an expansion of regulatory T cells (Tregs) has been demonstrated, which can suppress virus-specific CD4(+) T cell responses in vitro. However, the suppressive activity of Tregs on effector CD4(+) T cells in retroviral infection is less well documented in vivo. We took advantage of a transgenic mouse in which Tregs can be selectively depleted to determine the influence of such cells on retrovirus-specific CD4(+) T cell responses during an ongoing infection. Mice were infected with Friend retrovirus (FV), and Tregs were depleted during the acute phase of the infection. In nondepleted mice, activated CD4(+) T cells produced Th1-type cytokines but did not exhibit any antiviral cytotoxicity as determined in a major histocompatibility complex (MHC) class II-restricted in vivo cytotoxic T lymphocyte (CTL) assay. Depletion of Tregs significantly increased the numbers of virus-specific CD4(+) T cells and improved their cytokine production, whereas it induced only very little CD4(+) T cell cytotoxicity. However, after dual depletion of Tregs and CD8(+) T cells, conventional CD4(+) T cells developed significant cytotoxic activity against FV epitope-labeled target cells in vivo and contributed to the control of virus replication. Thus, both Tregs and CD8(+) T cells influence the cytotoxic activity of conventional CD4(+) T cells during an acute retroviral infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23536666      PMCID: PMC3648127          DOI: 10.1128/JVI.00432-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

2.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

3.  Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection.

Authors:  Gennadiy Zelinskyy; Anke R M Kraft; Simone Schimmer; Tanja Arndt; Ulf Dittmer
Journal:  Eur J Immunol       Date:  2006-10       Impact factor: 5.532

Review 4.  Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection.

Authors:  J Lieberman; P Shankar; N Manjunath; J Andersson
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice.

Authors:  Jeong Kim; Katharina Lahl; Shohei Hori; Christoph Loddenkemper; Ashutosh Chaudhry; Paul deRoos; Alexander Rudensky; Tim Sparwasser
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

6.  In vitro suppression of CD8+ T cell function by Friend virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Kim J Hasenkrug
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

Review 7.  Cytokines and HIV-1: interactions and clinical implications.

Authors:  K Kedzierska; S M Crowe
Journal:  Antivir Chem Chemother       Date:  2001-05

8.  Molecular mechanisms of treg-mediated T cell suppression.

Authors:  Angelika Schmidt; Nina Oberle; Peter H Krammer
Journal:  Front Immunol       Date:  2012-03-21       Impact factor: 7.561

9.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

10.  CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status.

Authors:  Audrey L Kinter; Margaret Hennessey; Alicia Bell; Sarah Kern; Yin Lin; Marybeth Daucher; Maria Planta; Mary McGlaughlin; Robert Jackson; Steven F Ziegler; Anthony S Fauci
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

View more
  22 in total

1.  Elimination of friend retrovirus in the absence of CD8+ T cells.

Authors:  Sachiyo Tsuji-Kawahara; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

2.  CD8+ T cells are essential for controlling acute friend retrovirus infection in C57BL/6 mice.

Authors:  Jara J Joedicke; Gennadiy Zelinskyy; Ulf Dittmer; Kim J Hasenkrug
Journal:  J Virol       Date:  2014-05       Impact factor: 5.103

3.  Reply to "CD8+ T cells are essential for controlling acute friend virus infection in C57BL/6 mice".

Authors:  Sachiyo Tsuji-Kawahara; Shiki Takamura; Masaaki Miyazawa
Journal:  J Virol       Date:  2014-05       Impact factor: 5.103

4.  Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy.

Authors:  Caroline Mangare; Sabine Tischer-Zimmermann; Agnes Bonifacius; Sebastian B Riese; Anna Christina Dragon; Rainer Blasczyk; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Transfus Med Hemother       Date:  2021-09-10       Impact factor: 3.747

5.  Immunodominance of Adenovirus-Derived CD8+ T Cell Epitopes Interferes with the Induction of Transgene-Specific Immunity in Adenovirus-Based Immunization.

Authors:  Dominik Schöne; Camilla Patrizia Hrycak; Sonja Windmann; Dennis Lapuente; Ulf Dittmer; Matthias Tenbusch; Wibke Bayer
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

6.  Default polyfunctional T helper 1 response to ample signal 1 alone.

Authors:  Luca Danelli; Georgina Cornish; Julia Merkenschlager; George Kassiotis
Journal:  Cell Mol Immunol       Date:  2020-04-20       Impact factor: 11.530

7.  Opposing Development of Cytotoxic and Follicular Helper CD4 T Cells Controlled by the TCF-1-Bcl6 Nexus.

Authors:  Tiziano Donnarumma; George R Young; Julia Merkenschlager; Urszula Eksmond; Nadine Bongard; Stephen L Nutt; Claude Boyer; Ulf Dittmer; Vu Thuy Khanh Le-Trilling; Mirko Trilling; Wibke Bayer; George Kassiotis
Journal:  Cell Rep       Date:  2016-11-01       Impact factor: 9.423

8.  Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection.

Authors:  Elisabeth Littwitz-Salomon; Ilseyar Akhmetzyanova; Cecilia Vallet; Sandra Francois; Ulf Dittmer; Kathrin Gibbert
Journal:  Retrovirology       Date:  2015-07-30       Impact factor: 4.602

9.  Distinct roles of NK cells in viral immunity during different phases of acute Friend retrovirus infection.

Authors:  Elisabeth Littwitz; Sandra Francois; Ulf Dittmer; Kathrin Gibbert
Journal:  Retrovirology       Date:  2013-11-01       Impact factor: 4.602

10.  Genomic and immunologic factors associated with viral pathogenesis in a lethal EV71 infected neonatal mouse model.

Authors:  Yingying Yue; Peng Li; Nannan Song; Bingqing Li; Zhihui Li; Yuqi Guo; Weidong Zhang; Ming Q Wei; Zhongtao Gai; Hong Meng; Jiwen Wang; Lizeng Qin
Journal:  Mol Med Rep       Date:  2016-03-31       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.